Jazz Pharmaceuticals plc Share Price

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
108 USD +0.57% Intraday chart for Jazz Pharmaceuticals plc -4.38% -12.22%
Sales 2024 * 4.05B 320B Sales 2025 * 4.37B 345B Capitalization 6.81B 538B
Net income 2024 * 432M 34.12B Net income 2025 * 598M 47.23B EV / Sales 2024 * 2.55 x
Net Debt 2024 * 3.54B 279B Net Debt 2025 * 2.21B 174B EV / Sales 2025 * 2.06 x
P/E ratio 2024 *
18.3 x
P/E ratio 2025 *
12.6 x
Employees 2,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.22%
More Fundamentals * Assessed data
Dynamic Chart
Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday MT
Sector Update: Health Care MT
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell MT
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study RE
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor CI
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 CI
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board CI
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 CI
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday MT
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer MT
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab CI
Transcript : Jazz Pharmaceuticals plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
More news
1 day+0.57%
1 week-4.38%
Current month+2.58%
1 month+3.88%
3 months-11.36%
6 months-10.95%
Current year-12.22%
More quotes
1 week
106.00
Extreme 106
115.24
1 month
103.10
Extreme 103.1
115.24
Current year
103.01
Extreme 103.01
134.17
1 year
103.01
Extreme 103.01
146.70
3 years
103.01
Extreme 103.01
186.22
5 years
86.88
Extreme 86.88
189.00
10 years
86.88
Extreme 86.88
194.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 28/02/03
President 52 15/03/20
Chief Tech/Sci/R&D Officer 57 28/05/19
Members of the board TitleAgeSince
Chief Executive Officer 60 28/02/03
Director/Board Member 66 12/05/13
Director/Board Member 62 31/12/08
More insiders
Date Price Change Volume
21/06/24 108 +0.57% 1,600,867
20/06/24 107.4 -4.72% 1,561,852
18/06/24 112.7 -1.62% 604,542
17/06/24 114.5 +1.43% 764,840

Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm

More quotes
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
108 USD
Average target price
179.6 USD
Spread / Average Target
+66.37%
Consensus